Pharmaceuticals News and Research

RSS

Ads for full-body scans to detect potential diseases, called into question

A burgeoning industry that sells full-body scans to detect potential diseases - without a doctor's referral - is running advertisements that frequently include unsubstantiated claims about the benefits of getting CT and MRI scans, while rarely providing information about the technology's limitations and risks.

13 Dec 2004

Successful human trial of obesity drug that mimicks metabolic effects of growth hormone

The AOD9604 molecule is a small orally active peptide modelled on one section of the human growth hormone molecule. Growth hormone naturally occurs in the body and has profound stimulatory effects on fat metabolism, with levels of the hormone typically becoming suppressed in the obese state.

13 Dec 2004

Interactive talking books delivered to Afghanistan

The United States Department of Health and Human Services has announced the delivery of thousands of interactive women's health books built with the LeapPad learning system technology to Afghanistan and an additional $6 million in aid to improve the health of the Afghan people.

13 Dec 2004

Molecular Achilles heel in the organism that causes pneumonia

Scientists have found a “molecular Achilles heel” in the organism that causes pneumonia, providing a target for the development of a new class of antibiotics that could eventually eradicate the disease.

13 Dec 2004

Labelling unhappy children as depressed may be harmful

Unhappiness among children seems to be rising, but labelling it as depression and prescribing antidepressants is ineffective and possibly harmful, warns a child psychiatrist in the BMJ.

13 Dec 2004

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays, as these assays offer a more accurate representation of the real-life cell model than the traditional enzyme- or antibody-based assays.

13 Dec 2004

Greater risk of heart attack associated with Vioxx than Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.

8 Dec 2004

African health care systems: what went wrong?

The last century witnessed unparalleled improvements in the health indicators of many countries in the African Region, particularly reductions in child mortality.

8 Dec 2004

New malaria enzyme laid bare with help of computer calculations

Using only computers, a research team at Uppsala University in Sweden has managed to reveal both the structure and the function of a newly discovered enzyme from the most dangerous malaria parasite, Plasmodium falciparum.

8 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

Electrochemical DNA chip that is able to detect DNA at very low concentrations

Toshiba Corporation has announced the development of a highly sensitive electrochemical DNA chip that is able to detect DNA at very low concentrations, a capability that will support advances in gene detection and analysis for individual treatment regimes, and the monitoring of healthy individuals for any predisposition to certain diseases.

6 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

5 Dec 2004

A vitamin B pill that drastically lowers blood levels of homocysteine could one day be used to prevent dementia

High blood levels of homocysteine are a risk factor for stroke and dementia, including Alzheimer’s disease. Raised levels damage nerves and blood vessels, and lead to a loss of brain tissue in patients.

4 Dec 2004

Two out of every three Americans know someone stricken by lung cancer

Two out of every three Americans know someone stricken by lung cancer, yet more than half of Americans don't realize that lung cancer is among the most lethal of cancers, according to a nationwide survey conducted on behalf of The Lung Cancer Online Foundation.

3 Dec 2004

FDA approval of cream to treat bacterial vaginosis

KV Pharmaceutical Company has announced that it has received approval from the United States Food and Drug Administration (FDA) to market Clindesse (clindamycin phosphate) Vaginal Cream, 2%, a single-dose prescription cream therapy indicated to treat bacterial vaginosis ("BV").

3 Dec 2004

Toxic proteins explain memory loss in Alzheimer's patients

Researchers at Northwestern University have discovered a molecular mechanism -- a tiny protein attacking nerve cells -- that could explain why the brain damage in early Alzheimer's disease results in memory loss and not other symptoms such as loss of balance or tremors.

1 Dec 2004

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

The two medicines (which are used in the treatment of AIDS) had been delisted by WHO in May this year due to non-compliance with international standards at the contract research organizations (CROs) hired by Cipla to conduct bioequivalence tests on the products.

30 Nov 2004

Novel anti-obesity compound shows promise for treatment of obesity

Arena Pharmaceuticals announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity.

30 Nov 2004

Rimonabant could be safer for treating obesity than previous weight-loss drugs

ECRI, a nonprofit health services research agency, recently published a Health Technology Forecast profile on a novel pharmaceutical agent that is in development for the treatment of obesity.

30 Nov 2004